Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y et al..  2017.  Recurrent genetic defects on chromosome 5q in myeloid neoplasms.. Oncotarget. 8(4):6483-6495.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ et al..  2015.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.. Cancer Cell. 28(1):15-28.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney ASophia, Papalexi E et al..  2015.  JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.. Cancer Discov. 5(3):316-31.

Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney ASophia et al..  2014.  Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.. Proc Natl Acad Sci U S A. 111(50):E5401-10.